What is the recommended use, efficacy, side effects, and alternatives of eflornithine (Vaniqa) topical cream for reducing unwanted facial hair in adult women?

Eflornithine Topical Cream for Unwanted Facial Hair in Women

Eflornithine 13.9% cream (Vaniqa) is FDA-approved and effective for reducing unwanted facial hair in women, with approximately 32% of patients achieving marked improvement after 24 weeks of twice-daily application, compared to 8% with placebo. 1

Mechanism and Application

• Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), the rate-limiting enzyme for follicular polyamine synthesis necessary for hair growth, thereby slowing hair follicle cell growth rate 2, 3
• Apply a thin layer to affected facial areas and adjacent areas under the chin twice daily, at least 8 hours apart, rubbing in thoroughly 1
• Do not wash the treated area for at least 4 hours after application 1
• Cosmetics or sunscreens may be applied after the cream has dried 1
• Continue hair removal techniques as needed; apply eflornithine at least 5 minutes after hair removal 1

Efficacy and Timeline

• Marked improvement is consistently seen at 8 weeks after treatment initiation and continues throughout 24 weeks of treatment 1
• Up to 60% of women experience slowed growth of unwanted facial hair, with improvement occurring gradually over 4-8 weeks or longer 2
• Hair growth returns to pretreatment levels within 8 weeks of treatment discontinuation 1, 3
• Percutaneous absorption is minimal (<1%) when applied twice daily to a 50 cm² area 3

Subgroup Efficacy

• White patients show greater benefit than non-White patients (37% vs. 22% success rate), though non-White patients (mostly Black subjects) still demonstrate significant treatment benefit (22% success on eflornithine vs. 5% on vehicle) 1
• Postmenopausal women show significant improvement (38% success compared to 0% with vehicle) 1

Side Effects and Safety Profile

• Most adverse events consist of minor skin irritation, with burning/stinging/tingling being markedly more common than placebo 3
• Under conditions of clinical use, eflornithine does not cause contact sensitization, phototoxic, or photosensitization reactions 1
• Irritation reactions can occur in susceptible individuals or under conditions of exaggerated use 1
• In cumulative irritation studies, the mean irritation score was 1.33 for eflornithine versus 0.76 for vehicle (both significantly lower than positive control at 3.09) 4
• Reported adverse events in clinical trials included pruritus (three subjects) and dry skin at test site (one subject) 4

Combination Therapy with Laser Treatment

• Eflornithine combined with laser hair removal produces significantly superior results compared to laser treatment alone 5
• Complete or almost complete hair removal was achieved in 93.5% of eflornithine-laser-treated sites versus 67.9% for placebo-laser-treated sites at 6 months 5
• From weeks 6 through 22, eflornithine-treated sides showed significant reduction in hair growth when combined with Nd:YAG or alexandrite laser therapy 6
• The safety profile for combination therapy is similar to eflornithine alone 6
• Patients demonstrate a clear preference for treatment with laser and eflornithine over other approaches 6

Alternative Treatments According to ACOG Guidelines

• The primary treatment for hirsutism has not been established, and treatment is often palliative rather than curative 7
• Oral contraceptives are used for ovarian suppression 7
• Antiandrogen drugs include spironolactone, flutamide, and finasteride 7
• Combined medical interventions (antiandrogen plus ovarian suppression agent) appear most effective, though the best specific agents are not definitively known 7
• Mechanical removal options include plucking, shaving, waxing, electrolysis, and laser vaporization, though multiple treatments are typically needed and concomitant medical management is usually necessary 7

Patient-Reported Outcomes

• Eflornithine statistically significantly reduced how bothered patients felt by their facial hair and the time spent removing, treating, or concealing facial hair 1
• Patient-observable differences were seen as early as 8 weeks after initiating treatment 1
• Self-assessment questionnaires showed eflornithine reduced the mean level of overall discomfort and bother by 33% versus 15% in placebo recipients 3

Important Clinical Caveats

• Eflornithine is the only FDA-labeled topical agent specifically for hirsutism treatment; additional benefits or risks for use in women with PCOS are unknown 7
• Women with severe inflammatory facial acne, pregnant women, and nursing mothers were excluded from clinical trials 1
• Clinical trials involved over 1370 women with skin types I-VI (68% White, 17% Black, 11% Hispanic-Latino, 2% Asian-Pacific Islander) 1
• Continuous use is required to maintain benefit, as hair growth returns to baseline within 8 weeks of stopping treatment 1, 3